KRON - Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting | Benzinga
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.
"We are excited to present our data at AACR showing that targeting p300's enzymatic KAT domain can selectively downregulate IRF4, a long sought after transcription factor dependency in multiple myeloma. Although p300 is an essential gene, our data show that through its relationship as a critical IRF4 cofactor, we can achieve selective antiproliferative effects against myeloma cells," said Charles Lin, Ph.D., Senior Vice President, Research and Development of Kronos ...